WAVEMAN · COMPANY

NPCE · Neuropace Inc

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

NPCE

Name: NeuroPace Inc (NPCE) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

NeuroPace Inc

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001528287

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+25.1%

XBRL, annual

NET MARGIN

-21.5%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

66 funds added or opened last quarter

below 54% of Medical Devices

REVENUE

+25.1% year over year

more than 79% of Medical Devices

MARGIN

-21.5% net margin

below 61% of Medical Devices

BUYBACKS

$49.5M repurchased, FY to 2025-12-31

more than 51% of Medical Devices

SHORT

2.4% of shares outstanding short · 3.9 days to cover · settled 2026-07-31

below 57% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

66 funds added or opened positions in the latest 13F quarter, of 115 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +61.4%

+61.4%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 66 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for NeuroPace Inc in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Morrell Martha

CHIEF MEDICAL OFFICER

SELL

2025-12-15

25,000.0

$399.2K

ORBIMED ADVISORS LLC

—

SELL

2025-05-14

34,000.0

$542.0K

ORBIMED ADVISORS LLC

—

SELL

2025-05-14

134,136.0

$2.1M

Morrell Martha

CHIEF MEDICAL OFFICER

SELL

2025-02-21

78,334.0

$1.1M

KCK LTD.

—

SELL

2025-02-20

5,270,845.0

$49.5M

71 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 66 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Polar Capital Holdings Plc

3,298,104.0 sh

$52.4M

Soleus Capital Management, L.P.

2,911,122.0 sh

$46.3M

First Light Asset Management, LLC

2,861,167.0 sh

$45.5M

MORGAN STANLEY

2,654,391.0 sh

$42.2M

BlackRock, Inc.

2,477,603.0 sh

$39.4M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

1290 Essex Small Cap Growth Fund

$856.6K POSITION · AS OF 2026-04-30

0.8%

Driehaus Micro Cap Growth Fund

$2.3M POSITION · AS OF 2026-03-31

0.5%

Osterweis Opportunity Fund

$984.7K POSITION · AS OF 2026-03-31

0.3%

NORTH SQUARE DYNAMIC SMALL CAP FUND

$1.4M POSITION · AS OF 2026-02-28

0.2%

Adara Smaller Companies Fund

$1.2M POSITION · AS OF 2026-02-28

0.2%

OneAscent Enhanced Small and Mid Cap ETF

$118.3K POSITION · AS OF 2026-02-28

0.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 4 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

1 ACTIVE

Not applicable

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$100.0M	$79.9M	$65.4M	$45.5M
GROSS PROFIT	$77.2M	$59.1M	$48.1M	$32.5M
OPERATING INCOME	$-16.3M	$-21.7M	$-27.2M	$-40.8M
NET INCOME	$-21.5M	$-27.1M	$-33.0M	$-47.1M
EPS (DILUTED)	-0.66	-0.93	-1.27	-1.91
OPERATING CASH FLOW	$-11.0M	$-17.9M	$-19.7M	$-36.9M
CASH	$21.7M	$13.4M	$18.1M	$6.6M
LONG-TERM DEBT	$58.9M	$59.5M	$57.0M	$52.9M
BUYBACKS	$49.5M	$0	—	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE